U.S. Life Sciences Stock News

Recent inflation data came in hotter than expected, and renewed credit risk worries hit bank stocks broadly, including First Financial Bankshares (FFIN). Investors reassessed exposure to problem loans and economically sensitive lenders. See our latest analysis for First Financial Bankshares. The recent 7.5% one day share price decline and 7.2% 7 day share price return, on a last close of US$30.93, sits alongside a mildly positive year to date share price return of 3.03%. At the same time, the...

In February 2026, Hertz Global Holdings, Inc. reported fourth-quarter 2025 results showing sales of US$2,028 million, with quarterly and full-year net losses narrowing year on year despite lower annual sales of US$8,504 million. The company attributed its wider-than-expected fourth-quarter loss to more than US$100 million of external disruptions, while outlining operational changes and fleet refresh plans aimed at improving earnings quality. Next, we’ll examine how these externally driven...

Target (TGT) heads into a closely watched earnings report and investor meeting this week, just as it commits to selling only cereals without certified synthetic colors, a move that has triggered fresh scrutiny of the stock. See our latest analysis for Target. Those cereal changes land at a time when Target’s share price has climbed 25.78% over the past 90 days and 7.89% over the last 30 days, even as the 1 year total shareholder return is slightly negative and longer term total shareholder...

In late February 2026, Progyny completed a share repurchase of 6,530,363 shares for US$159.4 million and filed a US$93.26 million common stock shelf registration tied to an ESOP, shortly after reporting quarterly and full-year 2025 results that showed higher sales, net income, and earnings per share than a year earlier. Despite these milestones and record 2025 revenue and adjusted EBITDA, management’s cautious 2026 revenue guidance, adjusted for a large client transition, drew attention to...

Lineage (LINE) is back in focus after reporting fourth quarter and full year 2025 results, which included a swing to a Q4 profit and a sharply smaller annual net loss, catching investors’ attention. See our latest analysis for Lineage. At a share price of US$40.52, Lineage has seen a 5.8% 7 day share price return, a 13.5% 30 day share price return, and a 14.4% year to date share price return. However, its 1 year total shareholder return of a 29.3% decline shows that recent momentum is...

Why Qnity Electronics (Q) Is Back on Investors’ Radar Qnity Electronics (Q) has drawn fresh attention after reporting Q4 2025 results that topped analyst revenue and earnings expectations, rolling out a multi year productivity plan, and approving a US$500 million share repurchase program. See our latest analysis for Qnity Electronics. The strong Q4 surprise, fresh 2026 net sales guidance and new M&A ambitions have coincided with powerful momentum, with a 30 day share price return of 31.8% and...

Ryder System recently reported fourth-quarter 2025 results that exceeded expectations and paired them with an upbeat earnings outlook for 2026, highlighting resilient performance across its logistics and vehicle services operations. This strong update comes shortly after sizable insider share sales by senior executives, drawing attention to how leadership actions align with Ryder’s growth and capital allocation plans. With Ryder’s better-than-expected quarter and optimistic 2026 guidance now...

iRhythm Holdings (IRTC) has drawn fresh attention after recent share price moves, with the stock showing a 4.6% decline over the past day and a 13.4% slide over the past month. See our latest analysis for iRhythm Holdings. The recent 1 day share price return of 4.6% decline adds to a 30 day share price return of 13.4% decline and a year to date share price return of 23.7% decline. At the same time, the 1 year total shareholder return of 22.6% shows a very different long term picture,...

Founder’s return and insider buying shift focus back to Simply Good Foods The Simply Good Foods (SMPL) story recently pivoted around founder Joe Scalzo’s return as CEO, his 2 million stock options, and a US$199,000 insider share purchase by the CFO, which has sharpened investor attention. See our latest analysis for Simply Good Foods. Despite the leadership shake up, Simply Good Foods’ recent share price return has been weak, with a 30 day share price decline of 9.11% and a 1 year total...

In recent weeks, Olema Pharmaceuticals announced the departure of its COO and CFO, Shane Kovacs, who will remain as a consultant through August 1, 2026, while CEO Sean Bohen temporarily assumes principal financial officer responsibilities. At the same time, continued Buy ratings from Citi and new coverage from Stifel have put a spotlight on palazestrant’s commercial potential in the sizeable endocrine therapy market and growing hedge fund interest in the stock. With this context, we’ll...

In late February 2026, NovoCure reported fourth-quarter 2025 revenue of US$174.35 million and a quarterly loss of US$24.5 million, alongside full-year 2025 revenue of US$655.35 million and a narrowed annual loss of US$136.23 million, while issuing 2026 net revenue guidance of US$675 million to US$705 million. Alongside these results, NovoCure secured U.S. FDA approval and began the commercial launch of Optune Pax for locally advanced pancreatic cancer, signaling a shift from a...

In recent months, Scorpio Tankers reported strong fourth-quarter results, with net income rising to US$128.1 million and daily TCE rates increasing year over year, while shifting its balance sheet from US$3.10 billions in net debt in 2021 to roughly US$334 million in net cash by early 2026. The company complemented this financial improvement with a higher quarterly dividend of US$0.45 per share and continued investment in scrubber-fitted vessels, pointing to a focus on cash returns and...

Turan Drilling and Engineering Company LLC, the joint venture between Helmerich & Payne and bp, recently secured a renewed offshore operations and maintenance contract from bp in the Caspian Sea, offshore Azerbaijan, with a firm 5-year term and three optional 1-year extensions that together could exceed US$1.00 billion in value. This long-term renewal underscores how Helmerich & Payne’s partnership role with bp in the Caspian Sea may support more predictable revenue and operational...

Preferred Bank (PFBC) has drawn fresh attention after recent trading left the stock around $87.72. Mixed returns over the past week, month and past 3 months are prompting investors to reassess its current valuation. See our latest analysis for Preferred Bank. The recent 1 day share price decline of 3.36% and year to date share price return of negative 8.57% contrast with a 1 year total shareholder return of 3.12%. This suggests shorter term momentum has cooled even as longer term holders have...

Dyne Therapeutics, Inc. reported a full-year 2025 net loss of US$446.21 million, with basic and diluted loss per share from continuing operations of US$3.47, and also filed a US$128.83 million shelf registration for 8,247,527 common shares related to its employee stock ownership plans. Amid this widening loss, Dyne is progressing its neuromuscular pipeline, including plans to seek U.S. Accelerated Approval for z-rostudirsen in Duchenne muscular dystrophy, which highlights how funding moves...

Madison Square Garden Entertainment Corp. recently disclosed that a data breach discovered on or about December 16, 2025 exposed personal information via a vulnerability in Oracle’s eBusiness Suite, prompting legal investigations by Edelson Lechtzin LLP on behalf of affected individuals. Beyond potential legal and remediation costs, this incident puts the company’s data security and operational controls under scrutiny at a time when it relies heavily on customer trust for its live...

F&G Annuities & Life, Inc. and Voya Financial, Inc. previously announced that F&G’s annuity solutions would be distributed through Voya’s Wealth Management platform, giving Voya financial professionals access to F&G products, education and support for retirement and income protection planning. This collaboration combines F&G’s product range with Voya’s advisory reach, potentially broadening F&G’s presence in the US retirement market and deepening advisor adoption of its annuity...

Relay Therapeutics, Inc. recently reported full-year 2025 results, with revenue rising to US$15.36 million from US$10.01 million and its net loss narrowing to US$276.48 million from US$337.71 million, while also securing FDA Breakthrough Therapy designation and advancing multiple 2026 data milestones for lead asset zovegalisib. Alongside a narrower basic loss per share of US$1.61 versus US$2.36 a year earlier, the company filed a US$96.18 million common-stock shelf registration tied to an...

Astec Industries, Inc. has now reported its fourth-quarter and full-year 2025 results, with Q4 sales rising to US$400.6 million from US$359.0 million and full-year sales reaching US$1.41 billion, while net income increased to US$38.8 million for 2025 and the Board maintained a quarterly dividend of US$0.13 per share payable in March 2026. Despite Q4 net income easing year on year, the company delivered record quarterly and annual sales, beat analyst earnings and revenue expectations,...

IMAX Corporation recently reported fourth-quarter 2025 revenue of US$125.21 million and full-year 2025 revenue of US$410.21 million, with annual net income rising to US$34.88 million even as quarterly net income softened. The company paired these record box office and revenue results with ongoing global network expansion and deeper local-language and live-event content partnerships, including a new collaboration with Apple TV to screen select 2026 Formula One races in IMAX theaters. We’ll...

What Pfizer’s Recent Share Performance Signals for Investors With no single headline event driving the move, Pfizer (PFE) has quietly posted positive returns over the past week, month, and past 3 months. This naturally raises questions about what is being priced into the stock. See our latest analysis for Pfizer. At a share price of $27.65, Pfizer’s recent 1 day share price return of 2.03%, 30 day share price return of 4.58%, and roughly 10% year to date share price return suggest momentum...

Chemed Corporation recently reported fourth-quarter 2025 results showing net income of US$76.75 million and full-year 2025 net income of US$265.24 million, both lower than the prior year, alongside 2026 adjusted earnings guidance of US$23.25–US$24.25 per diluted share. Despite ongoing share repurchases totaling US$2.62 billion since 2011, investors focused on pressure in VITAS and Roto-Rooter margins, including Medicare Cap constraints and water-restoration write-offs. We’ll now examine how...

In February 2026, Guardant Health reported fourth-quarter 2025 revenue of US$281.27 million and a net loss of US$128.49 million, filed a US$510.17 million shelf registration for 4,795,700 common shares tied to employee stock plans, and issued 2026 revenue guidance of US$1.25–1.28 billion. Alongside these filings and results, Guardant’s inclusion as a leading contributor in an institutional growth fund and commentary about volume-driven expansion and acquisition activity highlighted growing...

Jehoshaphat Research’s short report on GPGI (GPGI), centered on alleged overstatement of Husky Technologies’ financial metrics and the abrupt CEO and CFO resignations, has quickly become a key focus for traders assessing the stock. See our latest analysis for GPGI. GPGI’s latest short report comes after a year where the share price has moved sharply at times, with a 20.25% year to date share price return and a very large 3 year total shareholder return of about 4x. This is even with a recent...